Rimonabant is a selective cannabinoid-1 receptor blocker, which may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese. Rimonabant is generally well tolerated but the most common drugrelated adverse event reported in trials is nausea. We report a case of persistent vomiting associated with rimonabant therapy for reduction of body weight gain in a patient with paranoid schizophrenia, which resolved following discontinuation of medication and symptomatic treatment.
|Number of pages||2|
|Journal||German Journal of Psychiatry|
|Publication status||Published - 24-07-2013|
All Science Journal Classification (ASJC) codes
- Psychiatry and Mental health